A 2025 report from a bipartisan, congressionally chartered commission warns that China is closing in on a win, and the United ...

At September 30, 2025, Edesa had cash and cash equivalents of $10.8 million and working capital of $10.4 million. Subsequent to the fiscal year end, the company received $3.4 million in net proceeds, ...

The final draft of the FY 2026 National Defense Authorization Act (NDAA) includes the proposed BIOSECURE Act (the Act), which would place ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

House Democrats received a trove of images from Jeffrey Epstein's estate and released images of Donald Trump, Bill Clinton ...

Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors ...

As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. Those were not the only notable insider buying ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech ...

The aggregate gross proceeds to the Company from the offering were approximately $8.0 million before deducting the placement agent's fees and other offering expenses payable by the Company. The ...

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...

Speculative investors and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech ...